Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
This study aimed to explore the efficacy and biomarker explanation of IBI-322 Plus Lenvatinib on extensive stage small cell lung cancer who failed from first line PD-(L)1 inhibitors.
Small Cell Lung Cancer
DRUG: IBI-322 Plus Lenvatinib
ORR, Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects, 12 weeks
PFS, Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first), 1year|OS, Defined as the time from the start of treatment to the death of the subject due to any cause., 1 year
This study aimed to explore the efficacy and biomarker explanation of IBI-322 Plus Lenvatinib on extensive stage small cell lung cancer who failed from first line PD-(L)1 inhibitors.